ライフサイエンスコーパス: ROP

1 ROP also predicted the site of branch formation in the a

2 ROP was induced in 21 rats then two concentrations of 2-

3 preplus/plus disease (OR = 2.7, P = 0.003), ROP stage (OR = 4.2 for stage 3 ROP vs. no ROP, P = 0.00

4 The sensitivity for detecting type 1 ROP (32 infants) was 100% (95% CI, 89.3%-100%) with each

5 cted 452 of 459 infants who developed type 1 ROP (sensitivity, 98.5%; 95% CI, 96.9%-99.3%), reducing

6 n with ROP requiring treatment (i.e., type 1 ROP + advanced ROP) were born at an MGA of 30w4d (95% CI

7 received IVB as primary treatment for type 1 ROP and compare them to findings in patients with ROP th

8 All infants treated with IVB for type 1 ROP at a single institution from June 2013 to March 2018

9 was present at that examination, all type 1 ROP cases would be captured, and the number of examinati

10 ntial role of anti-VEGF treatment for type 1 ROP has become a focus in recent years, but the protract

11 ural outcomes than laser therapy when type 1 ROP is treated before 36 weeks' PMA.

12 The incidence of ROP and severe type 1 ROP that require treatment was 23.5 and 11.3% respective

13 d ROP, 5.3% had type 2 ROP, 27.3% had type 1 ROP, and 1.5% had advanced disease.

14 rved more frequently in children with type 1 ROP, appears essential for implementing timely treatment

15 ean outcomes were the sensitivity for type 1 ROP, reductions in infants requiring imaging or examinat

16 All inborn babies with type 1 zone 1 ROP at the Neonatal Intensive Care Unit of the Catholic

17 ts regarding the incidences of types 1 and 2 ROP.

18 AGING (trained reader grading of type 1 or 2 ROP initiates diagnostic examinations), and TARP (CHOP-R

19 osing AP-ROP (94% vs. 78%; P < 0.01), type 2 ROP or worse (92% vs. 84%; P = 0.04), and ROP requiring

20 out ROP, 22.0% had mild ROP, 5.3% had type 2 ROP, 27.3% had type 1 ROP, and 1.5% had advanced disease

21 26 ROP patients were divided into maintainers and improvers

22 P = 0.003), ROP stage (OR = 4.2 for stage 3 ROP vs. no ROP, P = 0.006), and blot hemorrhage (OR = 3.

23 es with referral-warranted (RW) ROP (stage 3 ROP, zone I ROP, plus disease) on diagnostic examination

24 separating 56 healthy controls (HC) from 35 ROP patients using rsFC (balanced accuracy of 65.5%, P <

25 ts who underwent LSV for stage 4A, 4B, and 5 ROP were retrospectively reviewed.

26 thod in reduction of neovascularization of a ROP rat model.

27 ulsion in regressing neovascularization of a ROP rat model.

28 ; synonym: INTERACTOR OF CONSTITUTIVE ACTIVE ROP b) directly interacts with RACB in yeast and in plan

29 effector interactor of constitutively active ROP (ICR1).

30 oagulation for achieving regression of acute ROP.

31 iring treatment (i.e., type 1 ROP + advanced ROP) were born at an MGA of 30w4d (95% CI, +/- 5d; range

32 Among 401 eyes with advanced ROP, 40 eyes (10.0%) had glaucoma during a mean of 3.06+

33 to visualize ROP in live cells do not affect ROP function.

34 which may be beneficial for more aggressive ROP.

35 An ROP severity score (1-9) was generated for each image us

36 2 ROP or worse (92% vs. 84%; P = 0.04), and ROP requiring treatment (89% vs. 79%; P < 0.01) was bett

37 h lobar and global cortical surface area and ROP was significantly negatively correlated with lobar a

38 ide a founding framework revealing auxin and ROP signaling of inner polar nuclear position with some

39 the underlying associations between BPD and ROP are not well characterized.

40 f the most potent neonatal diseases, BPD and ROP.

41 discovery of novel targets to treat BPD and ROP.

42 sm between the cell cycle, cytoskeleton, and ROP.

43 ght, prematurity, respiratory disorders, and ROP.

44 comprising laser-controlled ROP infants and ROP infants not requiring treatment.

45 n, image findings of the posterior pole, and ROP predict development of plus disease.

46 The specificity for diagnosing AP-ROP (94% vs. 78%; P < 0.01), type 2 ROP or worse (92% vs

47 , category, and aggressive posterior ROP (AP-ROP).

48 Data extracted from charts included baseline ROP information, visual acuity and other examination fin

49 Because ROP telemedicine is used more widely, development of sta

50 dependent, auxin sensitive, and regulated by ROP signaling.

51 The original CHOP ROP model correctly predicted 452 of 459 infants who dev

52 hiladelphia Retinopathy of Prematurity (CHOP ROP) model uses birth weight (BW), gestational age at bi

53 Conclusion and Relevance: The CHOP ROP model demonstrated high but not 100% sensitivity and

54 To validate the CHOP ROP model in a multicenter cohort that is large enough t

55 In the primary analysis, the CHOP ROP model was applied weekly to predict the risk of ROP.

56 ic examinations by an ophthalmologist), CHOP-ROP (birth weight and gestational age, with weekly weigh

57 hiladelphia Retinopathy of Prematurity (CHOP-ROP) postnatal weight gain predictive model are 2 approa

58 tes diagnostic examinations), and TARP (CHOP-ROP alarm initiates imaging, and imaging finding of seve

59 compared with demographic data and clinical ROP examination performed by experts.

60 wept-source (SS) OCT at the time of clinical ROP examinations.

61 itreous findings were compared with clinical ROP diagnoses.

62 r-eye agreements were found when considering ROP features at the first image session, at the last ima

63 Eight studies, 6 including laser-controlled ROP infants and 2 including ROP infants not requiring tr

64 preset subgroups comprising laser-controlled ROP infants and ROP infants not requiring treatment.

65 .5 +/- 285.0 g), 36 of 92 (39%) demonstrated ROP.

66 Overall, 65.8% of the infants developed ROP to some degree; 81.6% for infants of less than 1000

67 ociated with an increased risk of developing ROP among an unrestricted cohort but with a reduced risk

68 Among e-ROP infants, plus disease developed in 10% of infants at

69 ng Acute-Phase Retinopathy of Prematurity (e-ROP) Study telemedicine system of remote fundus image gr

70 ng Acute-Phase Retinopathy of Prematurity (e-ROP) study was conducted from May 1, 2011, to October 31

71 proaches to Evaluating of Acute-Phase ROP (e-ROP) Study.

72 ons when the risk cut point is surpassed), e-ROP IMAGING (trained reader grading of type 1 or 2 ROP i

73 was a post hoc analysis of a cohort in the e-ROP Study (a multicenter prospective telemedicine study)

74 Participants in the e-ROP Study were premature infants with a birth weight les

75 In the e-ROP study, 246 infants (492 eyes) were included in the a

76 had an IOH in an eye on at least 1 of the e-ROP visits.

77 pment that may be impacted by macular edema, ROP, or both.

78 oping haustoria, suggesting locally enhanced ROP activity.

79 As expected, ROP incidence and severity were higher in lower birth we

80 For ROP with 1.4 mg/L as Cl(2) chloramines, 0.5 log 1,4-diox

81 For ROP without chloramines, 0.5 log 1,4-dioxane removal was

82 d neonatal cryotherapy or laser ablation for ROP.

83 sed to analyze the intragrader agreement for ROP diagnosis by the ophthalmologists-in-training during

84 luorescein angiography after bevacizumab for ROP reveals abnormal vascular patterns in all eyes and N

85 basis for the within subject comparison for ROP trials.

86 mber of 115 infants who met the criteria for ROP screening in three neonatal intensive care units wer

87 with concurrent diagnostic examinations for ROP.

88 an readers graded each eye independently for ROP features in a 5 retinal-image set from each session.

89 1,259 premature infants at risk for ROP were evaluated.

90 included 7483 premature infants at risk for ROP with a known ROP outcome.

91 Eyes requiring neonatal treatment for ROP had associated worse BCVA at the age of 19 years.

92 s, worst stage of and need for treatment for ROP, and postnatal growth was obtained.

93 tment, and 28 (13.3%) received treatment for ROP.

94 evelopmental effects after anti-VEGF use for ROP treatment.

95 Plants lacking all four ROP genes comprised an unpatterned clump of spherical ce

96 The functional ROP fusion protein formed a steep gradient at the apical

97 tal Growth and Retinopathy of Prematurity (G-ROP) Study (a multicenter retrospective cohort study).

98 P) 1 study (2006-2012) and the prospective G-ROP 2 study (2015-2017).

99 owth and Retinopathy of Prematurity Study (G-ROP) 1 study (2006-2012) and the prospective G-ROP 2 stu

100 The G-ROP Study enrolled all infants undergoing ROP examinatio

101 atus, birth weight, gestational age, gender, ROP treatment method, postmenstrual age at treatment, an

102 nt tortuosity (VAT), and 16 eyes (18.0%) had ROP reactivation.

103 y of prematurity (ROP), 38% of eyes (84) had ROP not deemed to require treatment in the neonatal peri

104 ased on whether they had received IVB or had ROP that spontaneously regressed.

105 ate a naturalistic model representing the HC-ROP hyperplane.

106 rral-warranted (RW) ROP (stage 3 ROP, zone I ROP, plus disease) on diagnostic examination from the Te

107 s' postmenstrual age and followed up only if ROP was present at that examination, all type 1 ROP case

108 dictive model are 2 approaches for improving ROP screening efficiency.

109 d readers showed good inter-eye agreement in ROP characteristics, consistent with the high inter-eye

110 sistent with the high inter-eye agreement in ROP from clinical examinations by ophthalmologists in ot

111 atory factors reported to be dysregulated in ROP were similarly impaired in the lungs.

112 pleted by ophthalmologists with expertise in ROP.

113 With an increase in ROP stage from 0 to 2, the mean +/- standard deviation r

114 Risk of sNDI was not increased in ROP patients after IVB treatment.

115 sustained choroidal thinning is observed in ROP models.

116 but the role of prenatal growth patterns in ROP remains inconclusive.

117 integrity and retinal astrocyte survival in ROP.

118 laser-controlled ROP infants and 2 including ROP infants not requiring treatment, were included.

119 a birth weight less than 1251 g and a known ROP outcome enrolled between May 25, 2011, and October 3

120 nts undergoing ROP examinations with a known ROP outcome who were born between January 1, 2006, and D

121 emature infants at risk for ROP with a known ROP outcome.

122 . 29% without opacities; P = 0.003), maximum ROP stage (P = 0.001), preplus or plus disease (24% vs.

123 Infants meeting ROP screening criteria who were diagnosed with plus dise

124 immature retina without ROP, 22.0% had mild ROP, 5.3% had type 2 ROP, 27.3% had type 1 ROP, and 1.5%

125 l might be used reliably to guide a modified ROP screening schedule and decrease the number of examin

126 ariate analysis adjusted by BW and GA, nasal ROP border distance was a significant predictor of the s

127 oup (in accordance with the Mexican National ROP guidelines).

128 Program, compliant with the Mexican National ROP guidelines, over a 1-year period.

129 intensive care units follow Mexican National ROP guidelines, there have been few reports regarding th

130 Key architectures obtained through NCA ROP or in combination with other polymerization methods

131 nfants had a 4-5 x increased risk of needing ROP treatment (p < 0.001) compared to non-IUGR infants.

132 Previous treatments for neonatal ROP included peripheral laser ablation (n = 3), scleral

133 untreated EP eyes and those without neonatal ROP.

134 , ROP stage (OR = 4.2 for stage 3 ROP vs. no ROP, P = 0.006), and blot hemorrhage (OR = 3.1, P = 0.00

135 should explore handheld OCT as a noninvasive ROP screening tool.

136 t improvements (P < 0.01) in the accuracy of ROP diagnosis for plus disease, zone, stage, category, a

137 f plus disease, zone, stage, and category of ROP after completion of the educational intervention.

138 eeks, to monitor the incidence and course of ROP.

139 nt risk factors affecting the development of ROP in our study were: low gestational age, low birth we

140 t predictor of the subsequent development of ROP that was treated (odds ratio, 0.86 for every 10-pixe

141 cant predictor for subsequent development of ROP that was treated.

142 at may be associated with the development of ROP were collected manually.

143 insight into the development of ROP.

144 protective factor against the development of ROP.

145 ere significant regarding the development of ROP.

146 east once was associated with a diagnosis of ROP (62% vs. 29% without opacities; P = 0.003), maximum

147 Diagnosis of ROP requiring treatment was made at a mean postmenstrual

148 The cardinal features of ROP were replicated by this strategy, and the lungs of t

149 ders on premature patients with a history of ROP and no treatment during infancy who demonstrated lat

150 included preterm children with a history of ROP who had undergone laser therapy.

151 r study is aimed at finding the incidence of ROP and its association with some risk factors in Palest

152 The incidence of ROP and severe type 1 ROP that require treatment was 23.

153 The incidence of ROP is considered a relatively low percentage compared t

154 Location of ROP nasally at first imaging is a significant predictor

155 The diagnosis and management of ROP has changed over the past 40 years; the role of anti

156 Correspondingly, in a murine model of ROP, sEH-/- mice developed a larger central avascular zo

157 stigated the role of sEH in a mouse model of ROP.

158 ough phosphorylation-dependent modulation of ROP activity.

159 The occurrence of ROP was related to maternal preeclampsia in the full coh

160 that investigated the incidence and onset of ROP in a representative sample of children in Mexico.

161 istically involved in the pathophysiology of ROP.

162 triction (IUGR) as independent predictors of ROP, we performed a retrospective cohort study of patien

163 (67% vs. 48%; P = 0.04) and the presence of ROP (96% vs. 91%; P < 0.01).

164 required lensectomy owing to progression of ROP and/or presence of lens opacity, then the hazard of

165 The mean, median, and range of ROP vascular severity scores overall and for each examin

166 r prevalence after spontaneous regression of ROP.

167 restricted cohort but with a reduced risk of ROP among a restricted subcohort of P-VLBW infants.

168 ciation of maternal preeclampsia and risk of ROP among infants in an unrestricted birth cohort and a

169 rences, the association of a reduced risk of ROP among the P-VLBW subcohort also may reflect biases f

170 el was applied weekly to predict the risk of ROP.

171 repository of over 2500 unique image sets of ROP.

172 for RW-ROP, and 72.7% (0.63) for severity of ROP.

173 s bands predict the presence and severity of ROP.

174 ty to screen remote areas with a shortage of ROP providers, thereby reducing the burden of disease.

175 re more likely to be older at worst stage of ROP (p < 0.0001) and to develop postnatal growth failure

176 ts were more likely to have a worse stage of ROP and treatment-requiring ROP (both p < 0.0001) compar

177 tational age at birth, birthweight, stage of ROP at presentation, prior treatment (laser or cryothera

178 en paired eyes was 75.3% (0.65) for stage of ROP, 82.3% (0.68) for zone of ROP, 78.7% (0.51) for plus

179 rent incidence of various severity stages of ROP found in the United States and provide new.

180 images in 4 neonates with various stages of ROP that were obtained using a prototype handheld device

181 [range, 34-43 weeks]) with various stages of ROP: 3 in the neonatal intensive care unit and 1 in the

182 eria were as follows: comparative studies of ROP patients that (1) included IVB as a treatment arm, (

183 e primary concern regarding IVB treatment of ROP is the potential systemic side effects, especially t

184 In the treatment of ROP, ranibizumab 0.2 mg might be superior to laser thera

185 compared with laser therapy in treatment of ROP.

186 e therapy in the prevention and treatment of ROP.

187 ) for stage of ROP, 82.3% (0.68) for zone of ROP, 78.7% (0.51) for plus disease, 84.7% (0.56) for RW-

188 phasize the importance of prenatal growth on ROP development.

189 demia, bacteremia, respiratory disorders, or ROP.

190 undamental insights into the organocatalytic ROP of these specific six-membered asymmetric cyclic glu

191 Plants harboring tagged ROP4 and no other ROP genes were phenotypically normal.

192 l ((*)OH) to treat reverse osmosis permeate (ROP) in potable reuse treatment trains is inefficient, u

193 cine Approaches to Evaluating of Acute-Phase ROP (e-ROP) Study.

194 r treatment with bevacizumab for acute-phase ROP than after laser.

195 that MPK1 interacts with and phosphorylates ROP BINDING PROTEIN KINASE 1 (RBK1), a protein kinase th

196 members of the Rho-like GTPases from Plants (ROP) small GTPase family.

197 CMI1) as an interactor of the Rho of plants (ROP) effector interactor of constitutively active ROP (I

198 Rho of Plants (ROP) G-proteins are key components of cell polarization

199 Rho of Plants (ROPs) are GTPases that regulate polarity and patterned w

200 Ring-opening polymerization (ROP) of an allyl-substituted caprolactone monomer was ca

201 si-zwitterionic ring-opening polymerization (ROP) of an annulated isosorbide derivative (1,4:2,5:3,6-

202 witched between ring-opening polymerization (ROP) of BBL and CHO/CO2 copolymerization by the presence

203 e first aqueous ring-opening polymerization (ROP) of N-carboxyanhydrides (NCAs) using alpha-amino-pol

204 a tin-mediated ring-opening polymerization (ROP), generated their respective polyesters (PE) or poly

205 base-catalyzed ring-opening polymerizations (ROP) of six-membered cyclic d-glucose-based carbonates w

206 e, stage, category, and aggressive posterior ROP (AP-ROP).

207 ly classified as having aggressive posterior ROP (P = .004) and of Asian ethnicity (P = .008).

208 with zone I disease or aggressive posterior ROP), the disadvantages are that the ROP recurrence rate

209 h, Asian ethnicity, and aggressive posterior ROP.

210 plasia (BPD) and retinopathy of prematurity (ROP) are two debilitating disorders that develop in pret

211 (IVB) for type 1 retinopathy of prematurity (ROP) are uncertain.

212 dictors of worse retinopathy of prematurity (ROP) but the role of prenatal growth patterns in ROP rem

213 ic competency in retinopathy of prematurity (ROP) by ophthalmologists-in-training in Mexico.

214 fellow eyes for retinopathy of prematurity (ROP) features (stage, zone and plus disease) and severit

215 Severe Retinopathy of Prematurity (ROP) is a serious vasoproliferative disorder that can af

216 Retinopathy of prematurity (ROP) is characterized by an initial retinal avasculariza

217 Retinopathy of prematurity (ROP) is one of the targets for early detection and treat

218 ses of bilateral retinopathy of prematurity (ROP) received RLT.

219 ment used during retinopathy of prematurity (ROP) screening.

220 fants undergoing retinopathy of prematurity (ROP) screenings.

221 ing an automated retinopathy of prematurity (ROP) vascular severity score.

222 ed with neonatal retinopathy of prematurity (ROP), 38% of eyes (84) had ROP not deemed to require tre

223 Cryotherapy for Retinopathy of Prematurity (ROP), 4099 infants weighing less than 1251 g at birth un

224 tients with PDR, retinopathy of prematurity (ROP), and wet age-related macular degeneration (wet AMD)

225 to treat type 1 retinopathy of prematurity (ROP), but there remain concerns about systemic toxicity.

226 (OIR) resembling retinopathy of prematurity (ROP), loss of Casp-8 in ECs was beneficial, as pathologi

227 Retinopathy of prematurity (ROP), the primary cause of blindness in children, is a p

228 for treatment of retinopathy of prematurity (ROP), there are few data on their ocular efficacy, the a

229 plasia (BPD) and retinopathy of prematurity (ROP), with cortical maturational changes in VPT infants.

230 t the outcome of retinopathy of prematurity (ROP).

231 gery in advanced retinopathy of prematurity (ROP).

232 e risk of severe retinopathy of prematurity (ROP).

233 with or without retinopathy of prematurity (ROP).

234 infections, and retinopathy of prematurity (ROP).

235 om 169 eyes (1 eye excluded because of prior ROP treatment) at 36 +/- 1 weeks' PMA.

236 r 10-hours of CCT in recent onset psychosis (ROP) patients.

237 ective cohort study of patients who received ROP screening examinations at a level IV neonatal intens

238 side-chain functionalities in regioselective ROP processes.

239 P can occur rarely with previously regressed ROP.

240 ion in adolescents and adults with regressed ROP.

241 covariate adjustment were applied to relate ROP to preeclampsia among the full cohort and in a subco

242 depolymerization of the cytoskeleton removed ROP from the membrane only in recently divided cells, po

243 a worse stage of ROP and treatment-requiring ROP (both p < 0.0001) compared to non-IUGR infants.

244 model's sensitivity for treatment-requiring ROP.

245 sociation with ROP diagnosis and higher risk ROP features.

246 rwent handheld SD OCT at the time of routine ROP examinations.

247 nalysis of eyes with referral-warranted (RW) ROP (stage 3 ROP, zone I ROP, plus disease) on diagnosti

248 y eyes (153 [80.1%]) interpreted as being RW-ROP positive on imaging evaluation agreed with examinati

249 stational age, 24.8 [1.4] weeks) detected RW-ROP earlier than diagnostic examination (early) in 191 (

250 42.7%) eyes by about 15 days and detected RW-ROP in 123 infants (mean [SD] gestational age, 24.6 [1.5

251 n the examination subsequently documented RW-ROP.

252 (0.51) for plus disease, 84.7% (0.56) for RW-ROP, and 72.7% (0.63) for severity of ROP.

253 A total of 447 eyes had RW-ROP on diagnostic examination.

254 at was lower than previously used for severe ROP, was effective in this study, and could be tested in

255 Patients with more severe ROP had a higher incidence of glaucoma after lens-sparin

256 iates imaging, and imaging finding of severe ROP initiates diagnostic examinations).

257 ter photobleaching studies demonstrated that ROP dynamics do not depend on the cytoskeleton, acute de

258 ble to form gametophores, demonstrating that ROP is essentially for spatial patterning at the cellula

259 Here, we show that ROP INTERACTIVE PARTNER b (RIPb; synonym: INTERACTOR OF

260 We analyzed the results obtained by the ROP Detection and Treatment Program, compliant with the

261 he control group, trainees who completed the ROP tele-education system performed better on the postte

262 ows a hitherto unknown high activity for the ROP of rac-lactide at room temperature.

263 del was out-of-sample cross-validated in the ROP patients from the CCT trial to assess associations b

264 arily, the attentional gains occurred in the ROP patients who showed impaired SP at baseline only if

265 e eye was mosaicked, and measurements of the ROP border were made using Image J.

266 The eyes of the ROP children exhibited a narrower ACA, steeper iris curv

267 The eyes of the ROP children presented a narrower ACA and a more anterio

268 sterior ROP), the disadvantages are that the ROP recurrence rate is higher, and vigilant and extended

269 es focused on ablative therapy for threshold ROP, earlier treatment for type 1 or pre-threshold disea

270 The tiered approach to ROP screening was associated with a reduced number of ex

271 Black infants appeared less susceptible to ROP, of all severity categories, than nonblack infants.

272 Among all eyes, the disc-to-ROP border distance followed a consistent pattern, with

273 G-ROP Study enrolled all infants undergoing ROP examinations with a known ROP outcome who were born

274 Fundus photographs of all infants undergoing ROP screening examinations between July 1, 2011, and Dec

275 Three patients were female and 3 underwent ROP treatment as neonates.

276 ed polymer architectures from isosorbide via ROP.

277 ifficult to ensure that methods to visualize ROP in live cells do not affect ROP function.

278 The barley (Hordeum vulgare) ROP protein RACB is a susceptibility factor in the inter

279 (2) those that developed referral-warranted ROP but did not receive treatment, and (3) those that re

280 ent, 36 (17.1%) developed referral-warranted ROP not requiring treatment, and 28 (13.3%) received tre

281 7 (69.7%) did not develop referral-warranted ROP or receive treatment, 36 (17.1%) developed referral-

282 hose that never developed referral-warranted ROP or received treatment, (2) those that developed refe

283 proliferation in adolescents and adults with ROP can occur rarely with previously regressed ROP.

284 Light FP had a higher association with ROP diagnosis and higher risk ROP features.

285 examined 54 eyes of 29 preterm children with ROP and 134 eyes of 67 children born at term.

286 Premature children with ROP requiring treatment (i.e., type 1 ROP + advanced ROP

287 coefficient, 0.97 +/- 0.04) correlated with ROP stage (P = 0.02).

288 29% were diagnosed with ROP and 39.4% had light fundus pigmentation (FP).

289 detected in children formerly diagnosed with ROP; a similar sustained choroidal thinning is observed

290 Eyes with ROP not meeting the treatment threshold during infancy s

291 ts were compared among 3 groups of eyes with ROP: (1) those that never developed referral-warranted R

292 cademic medical center among 4 neonates with ROP in the neonatal intensive care unit and in the opera

293 e-field OCT and OCTA images in neonates with ROP using a prototype handheld OCT and OCTA device.

294 m) OCTA scans were obtained in patients with ROP in a single 2-second scan.

295 r patterns identified by FA in patients with ROP result from the disease process itself rather than a

296 nd compare them to findings in patients with ROP that spontaneously regressed.

297 tcomes compared with premature patients with ROP without requirement of treatment (group 1), although

298 Among 138 patients older than 10 years with ROP seen at our tertiary referral center from 2000 throu

299 s follows: 36.4% had immature retina without ROP, 22.0% had mild ROP, 5.3% had type 2 ROP, 27.3% had

300 rences in retinopathy outcomes, age at worst ROP stage, or postnatal growth failure.